Innovent Biologics, Inc.: all 216 studies
Page 3 of 3. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.
- Study of IBI318 in Participants With Advanced MalignanciesCompletedNCT03875157Phase 1
- Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With HypercholesterolemiaCompletedNCT03815812Phase 2
- A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular DegenerationCompletedNCT03814291Phase 1
- Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment FailureCompletedNCT03802240Phase 3
- A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.Status unknownNCT03794440Phase 2/3
- A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and LymphomasCompletedNCT03763149Phase 1
- First in Human Study of IBI101 in Chinese Subjects With Advanced Solid TumorsCompletedNCT03758001Phase 1
- Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )CompletedNCT03748134Phase 3
- Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric CancerCompletedNCT03745170Phase 3
- A Phase 1 Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI188 in Advanced MalignanciesCompletedNCT03717103Phase 1
- A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.CompletedNCT03545971Phase 1
- Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.CompletedNCT03366688Phase 1
- A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma PatientsCompletedNCT02945215Phase 1
- Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy VolunteersCompletedNCT02912247Phase 1
- Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing SpondylitisCompletedNCT02893254Phase 3
- A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma PatientsCompletedNCT02867566Phase 3